Company Description

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.

It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026.

PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.

PRF Technologies Ltd.

Country	Israel
Founded	2007
IPO Date	Sep 1, 2020
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	7
CEO	Efraim Cohen-Arazi

Contact Details

Address: 65 Yigal Alon St. Tel Aviv-Yafo, 6744316 Israel
Phone	972 3 7177050
Website	painreform.com

Stock Details

Ticker Symbol	PRFX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$8.00
CIK Code	1801834
CUSIP Number	M77798201
ISIN Number	IL0011651580
SIC Code	2834

Key Executives

Name	Position
Efraim Cohen-Arazi	Interim Chief Executive Officer and Director
Dr. Ehud Geller Ph.D.	Executive Chairman
Eyal Broder	Chief Financial Officer
Dr. Sigal Aviel eMBA, Ph.D.	Chief Operating Officer
Rita Keynan M.Sc.	Vice President of Pharmaceutical Operations

Latest SEC Filings

Date	Type	Title
Jul 21, 2026	6-K	Report of foreign issuer
Jul 15, 2026	6-K	Report of foreign issuer
Jul 8, 2026	6-K	Report of foreign issuer
Jun 29, 2026	EFFECT	Notice of Effectiveness
Jun 29, 2026	424B3	Prospectus
Jun 25, 2026	6-K	Report of foreign issuer
Jun 22, 2026	F-1	Registration statement for certain foreign private issuers
Jun 22, 2026	SCHEDULE 13G/A	Filing
Jun 18, 2026	6-K	Report of foreign issuer
Jun 16, 2026	SCHEDULE 13G/A	Filing

View All SEC Filings